Patents Represented by Attorney, Agent or Law Firm Paul J. Gaylo
  • Patent number: 7521462
    Abstract: The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of the central and/or peripheral nervous system.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: April 21, 2009
    Assignee: Eli Lilly and Company
    Inventors: Serge Louis Boulet, Barry Peter Clark, John Fairhurst, Peter Thaddeus Gallagher, Anette Margareta Johansson, Maria Ann Whatton, Virginia Ann Wood
  • Patent number: 7335660
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: February 26, 2008
    Assignee: Eli Lilly and Company
    Inventors: Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
  • Patent number: 6727255
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 27, 2004
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Patent number: 6403577
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: June 11, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Patent number: 6384281
    Abstract: A pharmaceutical compound of formula (I) in which R1 and R2 are each hydrogen or C1-4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group, said group being optionally substituted with 1 to 3 C1-4alkyl substituents, R3 is a naphythyl, indolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinolinyl or isoquinolinyl group, said group being optionally substituted, and n is 1 or 2; or a salt or ester thereof.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Martine Keenan, Sandra Ginette Milutinovic, David Edward Tupper
  • Patent number: 6355478
    Abstract: This invention describes a novel rhesus monkey receptor having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: March 12, 2002
    Assignee: Eli Lilly and Company
    Inventors: Melvyn Baez, Peiyi Yang
  • Patent number: 6313279
    Abstract: The present invention provides a human glutamate receptor and related DNA compounds useful not only in assays for potential pharmaceuticals but also in methods for molecular biology techniques.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: November 6, 2001
    Assignee: Eli Lilly and Company
    Inventors: J. Paul Burnett, Nancy G. Mayne, Robert L. Sharp, Yvonne M. Snyder
  • Patent number: 6312945
    Abstract: The present invention provides a human glutamate receptor and related DNA compounds useful not only in assays for potential pharmaceuticals but also in methods for molecular biology techniques.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: November 6, 2001
    Assignee: Eli Lilly and Company
    Inventors: J. Paul Burnett, Nancy G. Mayne, Robert L. Sharp, Yvonne M. Snyder
  • Patent number: 6281240
    Abstract: This invention provides methods of treating secretory diarrhea or cystic fibrosis in a mammal which comprises administering to a mammal in need thereof an effective amount of diarylsulfonylurea. This invention also describes specific diarylsulfonylureas for use in treating secretory diarrhea or cystic fibrosis.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: August 28, 2001
    Assignee: Eli Lilly and Company
    Inventor: Bruce D Schultz
  • Patent number: 6255494
    Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: July 3, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Robert Frederick Bruns, Jr., Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
  • Patent number: 6251928
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Patent number: 6245761
    Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: June 12, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
  • Patent number: 6242251
    Abstract: This invention describes a novel rhesus receptor having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: June 5, 2001
    Assignee: Eli Lilly and Company
    Inventors: Melvyn Baez, Peiyi Yang
  • Patent number: 6221838
    Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: April 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
  • Patent number: 6174921
    Abstract: This invention provides certain substituted benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: William J Ehlhardt, James E Ray, John E Toth
  • Patent number: 6175013
    Abstract: This invention provides a series of substituted 2-imidazolines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these compounds.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl
  • Patent number: 6150396
    Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of duloxetine.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: November 21, 2000
    Assignee: Eli Lilly and Company
    Inventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
  • Patent number: 6147115
    Abstract: This invention provides certain sulfonamide compounds, formulations, and a method for treating susceptible neoplasms in mammals using certain sulfonamide compounds.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, J. Jeffry Howbert, John S. Ward
  • Patent number: 6103510
    Abstract: The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Ruth Maria Kramer, Richard Todd Pickard, John David Sharp, Beth Ann Strifler
  • Patent number: 6093397
    Abstract: This invention describe a novel human amyloid precursor protein protease; nucleic acids encoding the protease; and methods employing the protease, as well as methods employing the nucleic acids encoding the protease.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Eric P Dixon, Edward M. Johnstone, Sheila P. Little